News

News

Date Title and Summary Additional Formats
Toggle Summary Ardelyx Announces Upcoming Presentations for Tenapanor at the American Society of Nephrology's Kidney Week Meeting 2015
FREMONT, Calif. , Oct. 28, 2015 /PRNewswire/ --  Ardelyx, Inc. ( NASDAQ : ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced nonclinical and clinical data for tenapanor, the Company's lead product candidate which is being
View HTML
Toggle Summary Ardelyx Appoints William Bertrand, Jr. to Its Board of Directors
FREMONT, Calif. , Oct. 26, 2015 /PRNewswire/ --  Ardelyx, Inc. ( NASDAQ : ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced that William Bertrand , Jr., joined the Company's Board of Directors. Mr.
View HTML
Toggle Summary Ardelyx to Present Phase 2 Data for Tenapanor in IBS-C Patients at the 2015 American College of Gastroenterology Annual Meeting
Sustained Response Results to Be Featured in Poster Presentation
View HTML
Toggle Summary Ardelyx Regains NaP2b Program from Sanofi
Allows Ardelyx to conduct further research on NaP2b and the complexities of phosphate transport and management
View HTML
Toggle Summary Ardelyx Reports Second Quarter 2015 Financial Results
Conference Call and Webcast Today at 8:00 a.m. ET
View HTML
Toggle Summary Ardelyx to Report Second Quarter 2015 Financial Results on August 12, 2015
FREMONT, Calif. , Aug. 5, 2015 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced that it will report second quarter 2015 financial results on Wednesday, August 12, 2015 .
View HTML
Toggle Summary Ardelyx to Present at the 2015 Wedbush PacGrow Healthcare Conference
FREMONT, Calif. , Aug. 5, 2015 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced that Mike Raab , Chief Executive Officer, will present an overview of the company at the Wedbush PacGrow
View HTML
Toggle Summary Ardelyx to Provide Updates on Research and Development Programs at Today's Inaugural R&D Day in New York City
Tenapanor development plans will be presented along with new data demonstrating sustained response in IBS-CDevelopment plans will be presented for RDX022, Ardelyx's next generation potassium binder for the treatment of hyperkalemiaIND filing targeted in 2H16 for RDX009, a TGR5 agonist that stimulates local secretion of GLP-1 and GLP-2 in the gutWebcast Today at 8:00 am EDT
View HTML
Toggle Summary Ardelyx to Host Inaugural R&D Investor Day in New York City on July 14, 2015
FREMONT, Calif. , June 30, 2015 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal and metabolic diseases, today announced that the Company will host its inaugural R&D Day on July 14, 2015 , from 8:00 a.m.- 1:00 pm EDT
View HTML
Toggle Summary Ardelyx to Present at the 2015 JMP Securities Life Sciences Conference
FREMONT, Calif. , June 16, 2015 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal and metabolic diseases, today announced that Mark Kaufmann , Chief Financial Officer, will present an overview of the company at the JMP
View HTML